Danaher Corporation (NYSE:DHR) is one of the best non-tech stocks to buy according to ******* ysts. Masimo, Danaher Corporation's (NYSE:DHR) specialty diagnostics solutions innovator of pulse oximetry and other patient monitoring solutions, announced on June 22, FDA 510(k) clearance for an opioid-induced respiratory depression detection capability integrated into the Radius VSM® wearable continuous patient monitor. Supported by Masimo's next-generation smartSET™ pulse oximetry sensor platform, the new feature employs advanced pattern recognition, which ******* yzes continuous physiologic data, allowing clinicians to identify early signs of respiratory compromise in hospital patients receiving opioid therapy.
In a separate development, Wolfe Research downgraded Danaher Corporation (NYSE:DHR) to Peer Perform from Outperform on June 1 without ******* igning a price target after ******* uming coverage of the name. It stated that growth forward and backward is similar, and Thermo Fisher is "a little cheaper on P/E". It added that the Masimo (MASI) transaction "confused us about DHR's identity."
Danaher Corporation (NYSE:DHR) designs, manufactures, and markets professional, medical, industrial, and commercial products and services, making it a significant diagnostics stock. It operates through Diagnostics, Biotechnology, Life Sciences, and Environmental and Applied Solutions.
While we acknowledge the potential of DHR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.